Akira Miyauchi, MD, PhD (Thyroid and Parathyroid surgery)
Kuma Hospital, Kobe, Japan
Dr. Miyauchi is President and COO of Kuma Hospital, Center for Excellence in Thyroid Care, Kobe, Japan. He is an endocrine surgeon, especially interested in thyroid and parathyroid diseases. He earned his MD and PhD at Osaka University Medical School in 1970 and 1978, respectively. He was Associate Professor of Department of Surgery, Kagawa Medical University until he was appointed to Vice President of Kuma Hospital in 1998. Since 2001, he is at his present position. About 2,000 operations, including about 1,300 thyroid cancer cases, are done every year at Kuma Hospital. He is currently serving as Chairman of the Asian Association of Endocrine Surgeons. He also served as Council of the International Association of Endocrine Surgeons until August 2015.
Prizes: Shichijo Prize, Japan Thyroid Association in May 1985.Prize of the best free paper, International Association of Endocrine Surgeons, in Sydney, Australia in September 1987.Hashimoto Prize, Tohoku Thyroid Society in March 1999. Miyake Prize, Japan Thyroid Association in November 2007.Best Endocrine Surgeon of the Year Prize, the Japan Endocrine Society in May 2008.The Asia Oceania Thyroid Association Prize (Nagataki-FUJI FILM Prize) in October 2015.
Publications: 519 papers in English and 496 papers in Japanese (as of February 25, 2017) International Invited Lectures and Special Lectures: 36 times, including ones at Massachusetts General Hospital, Yale University, Mayo Clinic, Johns Hopkins Hospital, University of California San Francisco, Seoul National University, and University of Rome Sapienza. (as of February 25, 2017).
Main Studies Performed:
1. Proposal of doubling times of serum calcitonin and thyroglobulin as powerful prognostic factors in medullary thyroid carcinoma and papillary thyroid carcinoma, respectively.
2. Reconstruction of the recurrent laryngeal nerve, including ansa cervicalis-to-RLN anastomosis, for recovery in phonation.
3. Proposal and conduction of active surveillance of low-risk papillary microcarcinoma of the thyroid.
4. Discovery of pyriform sinus fistula as a route of infection in patients with acute suppurative thyroiditis. Miyauchi proposed that the fistula is a remnant related to the migration of C cells from their origin, ultimobranchial body, to the developing thyroid.
5. Discovery of Intrathyroidal Epithelial Thymoma as an independent clinicopathologic entity of thyroid malignancies, which renamed CASTLE later.
6. Miyauchi clarified in collaboration with Mitsuru Ito that patients on l-thyroxine following total thyroidectomy require mildly TSH suppressive amount of l-thyroxine to achieve FT3 levels equivalent to their preoperative FT3 levels.
Terms of Appointment: May 2017 - Apr 2019; Jul 2019 - Jun 2020